HIV

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis (PrEP) vs on-demand PrEP.

Making pre-exposure prophylaxis (PrEP) more accessible can help to decrease the incidence of HIV in the US.

A model that can estimate the need for pre-exposure prophylaxis (PrEP) in the US can help to clarify use patterns to address HIV in local settings.

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes Zandraetta Tims-Cook, MD, MPH, AAHIVS

The Trump administration has ended a program seeking a vaccine for HIV, the first in a series of decisions that is leaving vaccine research and expertise behind.

About 40% of people living with HIV in an international survey did not make joint decisions regarding treatment with their provider despite reporting a high amount of trust.

People living with HIV who have taken highly active antiretroviral therapy can have hyperlipidemia predicted in advance by machine learning.

Sleep disorders and mental health complications were more common in adolescents or young adults who had HIV across the globe.

The CDC uses molecular cluster detection to find the transmission of HIV that could pinpoint where there are gaps in HIV care.

Patients with HIV can take both their antiretroviral therapy (ART) and treatment to prevent tuberculosis safely to prevent infection and further spread of the virus.

The ability to estimate their last viral load was high among women with HIV living in British Columbia, even in those with adverse sociodemographic factors.

A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based therapy in patients with HIV, showing noninferiority with over 90% of patients maintaining viral suppression without excess toxicity.

These guidelines act as an update to the 2016 guidelines for the use of nonoccupational postexposure prophylaxis (PEP) after exposure to HIV.

Viral suppression in HIV was more likely to be reported in women in Canada who had adherence to their antiretroviral therapy (ART) of 90% or higher.

Correlation to social drivers of health (SDOH) had an important correlation with polysubstance use.

A panelist discusses how the HIV patient population has aged significantly, with the average age in their clinic now exceeding 50 years and expected to soon exceed 65 years, and how these aging patients experience more comorbidities at younger ages than the general population while their HIV becomes easier to manage with simple regimens.

A panelist discusses how viral suppression in HIV patients means achieving undetectable virus levels (below 50 or 20 copies per ml), which prevents immune system damage and transmission to others, summarized as "undetectable equals untransmissible" (U=U).

Improving adherence to antiretroviral therapy (ART) in youth living with HIV requires interventions that target both family dynamics and any underlying mental illness.

Benjamin K. Chen, MD, PhD, discussed the next steps after the results of his study in genetic tagging showed promise in targeting HIV cells.

Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.

Benjamin Chen, MD, PhD, of the Icahn School of Medicine at Mount Sinai, discusses the implications of his new study involving genetically tagging immune cells with latent HIV.

Women living with HIV in Canada were found to have worse wellbeing when they had adversities related to social determinants of health (SDOH).